Halozyme Therapeutics, Inc. (HALO)
80.45
+3.53
(+4.59%)
USD |
NASDAQ |
Feb 13, 14:14
Halozyme Therapeutics Free Cash Flow : 602.40M for Sept. 30, 2025
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Johnson & Johnson | 19.70B |
| Merck & Co., Inc. | 13.05B |
| AIM ImmunoTech, Inc. | -13.33M |
| Stryker Corp. | 4.283B |
| Skye Bioscience, Inc. | -41.53M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 178.60M |
| Cash from Investing (Quarterly) | 201.61M |
| Cash from Financing (Quarterly) | -22.40M |
| Free Cash Flow Per Share (Quarterly) | 1.435 |
| Free Cash Flow to Equity (Quarterly) | 173.91M |
| Free Cash Flow to Firm (Quarterly) | 179.00M |
| Free Cash Flow Yield | 5.97% |